Brief: SynAct Pharma Q2 Sales SEK 0
20/08/2025 06:30
Aug 20 (Reuters) - SynAct Pharma Q2 cash flow from operating activities SEK -18.788 million. Q2 adjusted EPS SEK -0.56 Q2 operating expenses SEK 30.345 million Q2 net income SEK -27.522 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026